United States Biotechnology & Medical Research

Clearside Biomedical Inc (CLSD)

Track

Stock chart
Ticker: CLSD Exchange: NMS
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


Subscribe to get access to the transaction volume chart and in-chart transaction details
• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Activity signal Earnings
Top insiders
Trades
Thorp Clay
1 purchase — total 13,800 USD
Buy 24 Feb 2025
Value US$4,124,304.85 | Price 366.31 | Shares 89,064
Buy 1 Nov 2024
Value US$3,104,742.54 | Price 279.08 | Shares 54,640
Buy 24 Jun 2024
Value US$24,910.00 | Price 1.06 | Shares 23,500
Buy 15 May 2024
Value US$10,235.03 | Price 1.31 | Shares 7,813
Buy 18 Apr 2024
Value US$121,277.00 | Price 1.30 | Shares 93,290
Buy 17 Apr 2024
Value US$8,387.50 | Price 1.25 | Shares 6,710
Buy 20 Mar 2024
Value US$48,000.00 | Price 1.60 | Shares 30,000
Buy 7 Feb 2024
Value US$599,999.40 | Price 1.35 | Shares 444,444
Proposed sale 19 Jan 2024
Value US$22,779.00 | Price 1.27 | Shares 18,000
Proposed sale 19 Jan 2024
Value US$16,515.00 | Price 1.28 | Shares 12,900
Sale 19 Jan 2024
Value US$16,512.00 | Price 1.28 | Shares 12,900
Sale 19 Jan 2024
Value US$22,860.00 | Price 1.27 | Shares 18,000
Buy 1 Nov 2023
Value US$47,901.18 | Price 0.74 | Shares 64,366
Buy 31 Oct 2023
Value US$51,536.97 | Price 0.73 | Shares 70,812
Buy 30 Oct 2023
Value US$411.00 | Price 0.69 | Shares 600
Buy 3 Oct 2023
Value US$8,600.00 | Price 0.86 | Shares 10,000
Buy 25 Sep 2023
Value US$8,600.00 | Price 0.86 | Shares 10,000
Planned sale 20 Jan 2023
Value US$20,139.00 | Price 1.47 | Shares 13,700
Planned sale 19 Jan 2023
Value US$29,243.80 | Price 1.46 | Shares 20,030
Planned sale 19 Jan 2023
Value US$21,045.00 | Price 1.50 | Shares 14,030
Planned sale 10 Jan 2023
Value US$3,515.40 | Price 1.62 | Shares 2,170
Buy 21 Dec 2022
Value US$14,266.00 | Price 1.02 | Shares 14,000
Buy 17 Nov 2022
Value US$39,900.00 | Price 1.33 | Shares 30,000
Planned sale 19 Jan 2022
Value US$18,460.97 | Price 2.09 | Shares 8,833
Planned sale 19 Jan 2022
Value US$22,896.00 | Price 2.12 | Shares 10,800
Planned sale 19 Jan 2022
Value US$19,276.50 | Price 2.13 | Shares 9,050
Planned sale 11 Jan 2022
Value US$12,546.00 | Price 2.46 | Shares 5,100
Buy 16 Aug 2021
Value US$17,040.00 | Price 5.68 | Shares 3,000
Planned sale 21 Jun 2021
Value US$12,839.06 | Price 4.37 | Shares 2,938
Planned sale 21 Jun 2021
Value US$16,236.66 | Price 4.38 | Shares 3,707
Planned sale 19 Mar 2021
Value US$9,503.40 | Price 2.82 | Shares 3,370
Buy 12 Mar 2021
Value US$15,525.00 | Price 3.11 | Shares 5,000
Planned sale 2 Mar 2021
Value US$20,220.00 | Price 3.37 | Shares 6,000
Planned sale 10 Feb 2021
Value US$145,627.39 | Price 4.43 | Shares 32,873
Buy 6 Jan 2021
Value US$999,988.25 | Price 2.85 | Shares 350,750
Buy 24 Dec 2020
Value US$99,896.80 | Price 1.95 | Shares 51,195
Planned sale 21 Dec 2020
Value US$6,893.10 | Price 2.07 | Shares 3,330
Buy 2 Dec 2020
Value US$105,051.10 | Price 1.95 | Shares 53,900
Buy 24 Nov 2020
Value US$102,045.80 | Price 1.65 | Shares 62,000
Buy 16 Nov 2020
Value US$104,928.80 | Price 1.69 | Shares 62,000
Planned sale 22 Sep 2020
Value US$21,323.49 | Price 1.59 | Shares 13,411
Buy 18 Aug 2020
Value US$9,943.08 | Price 1.78 | Shares 5,586
Buy 13 Aug 2020
Value US$82,560.00 | Price 1.65 | Shares 50,000
Buy 12 Aug 2020
Value US$489,120.00 | Price 1.63 | Shares 300,000
Planned sale 1 Jun 2020
Value US$28,184.96 | Price 1.88 | Shares 14,992
Buy 20 May 2020
Value US$9,250.00 | Price 1.85 | Shares 5,000
Planned sale 12 May 2020
Value US$63,978.50 | Price 1.99 | Shares 32,150
Buy 12 Nov 2019
Value US$8,550.00 | Price 1.14 | Shares 7,500
Buy 11 Nov 2019
Value US$13,920.00 | Price 1.16 | Shares 12,000
Buy 15 Mar 2019
Value US$13,600.00 | Price 1.36 | Shares 10,000
Buy 6 Dec 2018
Value US$10,880.00 | Price 1.36 | Shares 8,000
Buy 4 Jun 2018
Value US$99,770.00 | Price 9.07 | Shares 11,000
Sale 18 May 2018
Value US$804,589.24 | Price 13.16 | Shares 61,139
Sale 17 May 2018
Value US$1,303,000.00 | Price 13.03 | Shares 100,000
Buy 23 Mar 2018
Value US$5,895.00 | Price 11.79 | Shares 500
Sale 23 Mar 2018
Value US$62,876.62 | Price 12.02 | Shares 5,231
Buy 22 Mar 2018
Value US$89,175.00 | Price 11.89 | Shares 7,500
Sale 22 Mar 2018
Value US$405,914.10 | Price 12.07 | Shares 33,630
Sale 21 Mar 2018
Value US$1,227,000.00 | Price 12.27 | Shares 100,000
Planned sale 7 Dec 2017
Value US$30,650.00 | Price 6.13 | Shares 5,000
Planned sale 6 Dec 2017
Value US$91,350.00 | Price 6.09 | Shares 15,000
Planned sale 5 Dec 2017
Value US$95,550.00 | Price 6.37 | Shares 15,000
Planned sale 16 Nov 2017
Value US$34,950.00 | Price 6.99 | Shares 5,000
Planned sale 15 Nov 2017
Value US$104,850.00 | Price 6.99 | Shares 15,000
Planned sale 14 Nov 2017
Value US$105,300.00 | Price 7.02 | Shares 15,000
Planned sale 19 Oct 2017
Value US$3,124.00 | Price 7.81 | Shares 400
Planned sale 19 Oct 2017
Value US$28,116.00 | Price 7.81 | Shares 3,600
Planned sale 18 Oct 2017
Value US$3,128.00 | Price 7.82 | Shares 400
Planned sale 18 Oct 2017
Value US$28,152.00 | Price 7.82 | Shares 3,600
Planned sale 5 Oct 2017
Value US$50,040.00 | Price 8.34 | Shares 6,000
Planned sale 4 Oct 2017
Value US$120,260.00 | Price 8.59 | Shares 14,000
Planned sale 3 Oct 2017
Value US$129,600.00 | Price 8.64 | Shares 15,000
Planned sale 15 Sep 2017
Value US$75,400.00 | Price 7.54 | Shares 10,000
Planned sale 14 Sep 2017
Value US$45,120.00 | Price 7.52 | Shares 6,000
Planned sale 13 Sep 2017
Value US$63,665.00 | Price 7.49 | Shares 8,500
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2025-02-24 2025-02-24 B Purchase
3.8
Thorp Clay
Non-Executive Director
89,064 +37.7%
366.31
US$4,124,305 		89,064 +37.7% 366.31 US$4,124,305
2024-11-04 2024-11-01 B Purchase
2.0
Chong Ngai Hang Victor

Chief Medical Officer

Officer
54,640 -48.2%
279.08
US$3,104,743 		54,640 -48.2% 279.08 US$3,104,743
2024-06-24 2024-06-24 B Purchase
2.0
Chong Ngai Hang Victor

Chief Medical Officer

Officer
52,054 +47.1%
455.04
US$4,398,049 		52,054 +47.1% 455.04 US$4,398,049
2024-05-15 2024-05-15 B Purchase
3.2
YERXA BENJAMIN R
Non-Executive Director
7,813 +77.0%
1.31
US$10,235 		7,813 +77.0% 1.31 US$10,235
2024-04-19 2024-04-18 B Purchase
3.3
Gibney Anthony S
Non-Executive Director
93,290 +1390.3%
1.30
US$121,277 		93,290 +1390.3% 1.30 US$121,277
2024-04-19 2024-04-17 B Purchase
3.3
Gibney Anthony S
Non-Executive Director
6,710 +inf%
1.25
US$8,388 		6,710 +inf% 1.25 US$8,388
2024-03-20 2024-03-20 B Purchase
2.0
Chong Ngai Hang Victor

CHIEF MEDICAL OFFICER

Officer
30,000 +inf%
1.60
US$48,000 		30,000 +inf% 1.60 US$48,000
2024-02-09 2024-02-07 B Purchase
3.3
WHITMORE BRADFORD T
Large shareholder
444,444 +11.0%
1.35
US$599,999 		444,444 +11.0% 1.35 US$599,999
2024-01-19 2024-01-19 PrS Proposed sale
2.7
George Lasezkay

Officer

Officer
18,000
1.27
US$22,779 		18,000 1.27 US$22,779
2024-01-19 2024-01-19 PrS Proposed sale
2.1
Charles Deignan

Officer

Officer
12,900
1.28
US$16,515 		12,900 1.28 US$16,515
2024-01-19 2024-01-19 S Sale
2.1
Deignan Charles A.

Chief Financial Officer

Officer
12,900 -3.2%
1.28
US$16,512 		12,900 -3.2% 1.28 US$16,512
2024-01-19 2024-01-19 S Sale
2.7
LASEZKAY GEORGE M

CEO

Executive Director
18,000 -3.7%
1.27
US$22,860 		18,000 -3.7% 1.27 US$22,860
2023-11-01 2023-11-01 B Purchase
3.3
WHITMORE BRADFORD T
Large shareholder
64,366 +1.6%
0.74
US$47,901 		64,366 +1.6% 0.74 US$47,901
2023-11-01 2023-10-31 B Purchase
3.3
WHITMORE BRADFORD T
Large shareholder
70,812 +1.8%
0.73
US$51,537 		70,812 +1.8% 0.73 US$51,537
2023-11-01 2023-10-30 B Purchase
3.3
WHITMORE BRADFORD T
Large shareholder
600 +0.0%
0.69
US$411 		600 +0.0% 0.69 US$411
2023-10-04 2023-10-03 B Purchase
3.7
Hutson Nancy J
Non-Executive Director
10,000 +12.0%
0.86
US$8,600 		10,000 +12.0% 0.86 US$8,600
2023-09-25 2023-09-25 B Purchase
3.8
Thorp Clay
Non-Executive Director
10,000 +32.8%
0.86
US$8,600 		10,000 +32.8% 0.86 US$8,600
2023-01-20 2023-01-20 PlS Planned sale
Ciulla Thomas

Chief Medical Officer

Officer
13,700 -4.5%
1.47
US$20,139 		13,700 -4.5% 1.47 US$20,139
2023-01-20 2023-01-19 PlS Planned sale
2.7
LASEZKAY GEORGE M

CEO

Executive Director
20,030 -4.0%
1.46
US$29,244 		20,030 -4.0% 1.46 US$29,244
2023-01-20 2023-01-19 PlS Planned sale
2.1
Deignan Charles A.

Chief Financial Officer

Officer
14,030 -3.7%
1.50
US$21,045 		14,030 -3.7% 1.50 US$21,045
2023-01-11 2023-01-10 PlS Planned sale
Ciulla Thomas

Chief Medical Officer

Officer
2,170 -0.7%
1.62
US$3,515 		2,170 -0.7% 1.62 US$3,515
2022-12-21 2022-12-21 B Purchase
3.8
Thorp Clay
Non-Executive Director
14,000 +84.7%
1.02
US$14,266 		14,000 +84.7% 1.02 US$14,266
2022-11-21 2022-11-17 B Purchase
3.7
Hutson Nancy J
Non-Executive Director
30,000 +56.6%
1.33
US$39,900 		30,000 +56.6% 1.33 US$39,900
2022-01-20 2022-01-19 PlS Planned sale
2.1
Deignan Charles A.

Chief Financial Officer

Officer
8,833 -2.5%
2.09
US$18,461 		8,833 -2.5% 2.09 US$18,461
2022-01-20 2022-01-19 PlS Planned sale
2.7
LASEZKAY GEORGE M

CEO

Executive Director
10,800 -2.1%
2.12
US$22,896 		10,800 -2.1% 2.12 US$22,896
2022-01-20 2022-01-19 PlS Planned sale
Ciulla Thomas

Chief Medical Officer

Officer
9,050 -3.0%
2.13
US$19,276 		9,050 -3.0% 2.13 US$19,276
2022-01-13 2022-01-11 PlS Planned sale
2.7
LASEZKAY GEORGE M

CEO

Executive Director
5,100 -1.2%
2.46
US$12,546 		5,100 -1.2% 2.46 US$12,546
2021-08-17 2021-08-16 B Purchase
3.7
Hutson Nancy J
Non-Executive Director
3,000 +30.0%
5.68
US$17,040 		3,000 +30.0% 5.68 US$17,040
2021-06-23 2021-06-21 PlS Planned sale
2.1
Deignan Charles A.

Chief Financial Officer

Officer
2,938 -0.9%
4.37
US$12,839 		2,938 -0.9% 4.37 US$12,839
2021-06-23 2021-06-21 PlS Planned sale
2.7
LASEZKAY GEORGE M

CEO

Executive Director
3,707 -0.9%
4.38
US$16,237 		3,707 -0.9% 4.38 US$16,237
2021-03-23 2021-03-19 PlS Planned sale
2.7
LASEZKAY GEORGE M

CEO

Executive Director
3,370 -0.8%
2.82
US$9,503 		3,370 -0.8% 2.82 US$9,503
2021-03-15 2021-03-12 B Purchase
3.7
Hutson Nancy J
Non-Executive Director
5,000 +100.0%
3.11
US$15,525 		5,000 +100.0% 3.11 US$15,525
2021-03-03 2021-03-02 PlS Planned sale
2.7
LASEZKAY GEORGE M

CEO

Executive Director
6,000 -1.4%
3.37
US$20,220 		6,000 -1.4% 3.37 US$20,220
2021-02-12 2021-02-10 PlS Planned sale
3.8
Thorp Clay
Non-Executive Director
32,873 -0.9%
4.43
US$145,627 		32,873 -0.9% 4.43 US$145,627
2021-01-07 2021-01-06 B Purchase
3.3
WHITMORE BRADFORD T
Large shareholder
350,750 +11.0%
2.85
US$999,988 		350,750 +11.0% 2.85 US$999,988
2020-12-28 2020-12-24 B Purchase
3.3
WHITMORE BRADFORD T
Large shareholder
51,195 +1.6%
1.95
US$99,897 		51,195 +1.6% 1.95 US$99,897
2020-12-23 2020-12-21 PlS Planned sale
2.7
LASEZKAY GEORGE M

CEO

Executive Director
3,330 -1.1%
2.07
US$6,893 		3,330 -1.1% 2.07 US$6,893
2020-12-02 2020-12-02 B Purchase
3.3
WHITMORE BRADFORD T
Large shareholder
53,900 +1.8%
1.95
US$105,051 		53,900 +1.8% 1.95 US$105,051
2020-11-24 2020-11-24 B Purchase
3.3
WHITMORE BRADFORD T
Large shareholder
62,000 +2.1%
1.65
US$102,046 		62,000 +2.1% 1.65 US$102,046
2020-11-16 2020-11-16 B Purchase
3.3
WHITMORE BRADFORD T
Large shareholder
62,000 +2.1%
1.69
US$104,929 		62,000 +2.1% 1.69 US$104,929
2020-09-24 2020-09-22 PlS Planned sale
2.7
LASEZKAY GEORGE M

CEO

Executive Director
13,411 -4.2%
1.59
US$21,323 		13,411 -4.2% 1.59 US$21,323
2020-08-18 2020-08-18 B Purchase
2.3
Humphries William D.
Non-Executive Director
5,586 +inf%
1.78
US$9,943 		5,586 +inf% 1.78 US$9,943
2020-08-13 2020-08-13 B Purchase
3.3
WHITMORE BRADFORD T
Large shareholder
50,000 +1.7%
1.65
US$82,560 		50,000 +1.7% 1.65 US$82,560
2020-08-13 2020-08-12 B Purchase
3.3
WHITMORE BRADFORD T
Large shareholder
300,000 +11.5%
1.63
US$489,120 		300,000 +11.5% 1.63 US$489,120
2020-06-03 2020-06-01 PlS Planned sale
2.1
Deignan Charles A.

Chief Financial Officer

Officer
14,992 -6.4%
1.88
US$28,185 		14,992 -6.4% 1.88 US$28,185
2020-05-21 2020-05-20 B Purchase
3.7
Hutson Nancy J
Non-Executive Director
5,000 +inf%
1.85
US$9,250 		5,000 +inf% 1.85 US$9,250
2020-05-13 2020-05-12 PlS Planned sale
2.7
LASEZKAY GEORGE M

CEO

Executive Director
32,150 -9.4%
1.99
US$63,978 		32,150 -9.4% 1.99 US$63,978
2019-11-13 2019-11-12 B Purchase
2.1
Deignan Charles A.

Chief Financial Officer

Officer
7,500 +3.8%
1.14
US$8,550 		7,500 +3.8% 1.14 US$8,550
2019-11-12 2019-11-11 B Purchase
2.7
LASEZKAY GEORGE M

CEO

Executive Director
12,000 +5.7%
1.16
US$13,920 		12,000 +5.7% 1.16 US$13,920
2019-03-18 2019-03-15 B Purchase
2.1
Deignan Charles A.

Chief Financial Officer
10,000 +15.1%
1.36
US$13,600 		10,000 +15.1% 1.36 US$13,600
2018-12-06 2018-12-06 B Purchase
3.8
Thorp Clay
Non-Executive Director Large shareholder
8,000 +inf%
1.36
US$10,880 		8,000 +inf% 1.36 US$10,880
2018-06-04 2018-06-04 B Purchase
2.0
White Daniel H.

President and CEO

Executive Director
11,000 +2.3%
9.07
US$99,770 		11,000 +2.3% 9.07 US$99,770
2018-05-21 2018-05-18 S Sale
3.8
Thorp Clay
Non-Executive Director Large shareholder
61,139 -1.7%
13.16
US$804,589 		61,139 -1.7% 13.16 US$804,589
2018-05-21 2018-05-17 S Sale
3.8
Thorp Clay
Non-Executive Director Large shareholder
100,000 -2.8%
13.03
US$1,303,000 		100,000 -2.8% 13.03 US$1,303,000
2018-03-26 2018-03-23 B Purchase
2.1
Deignan Charles A.

Chief Financial Officer
500 +0.8%
11.79
US$5,895 		500 +0.8% 11.79 US$5,895
2018-03-23 2018-03-23 S Sale
3.8
Thorp Clay
Large shareholder
5,231 -0.1%
12.02
US$62,877 		5,231 -0.1% 12.02 US$62,877
2018-03-23 2018-03-22 B Purchase
3.5
Cagle Gerald D.
7,500 +47.0%
11.89
US$89,175 		7,500 +47.0% 11.89 US$89,175
2018-03-23 2018-03-22 S Sale
3.8
Thorp Clay
Large shareholder
33,630 -0.9%
12.07
US$405,914 		33,630 -0.9% 12.07 US$405,914
2018-03-23 2018-03-21 S Sale
3.8
Thorp Clay
Large shareholder
100,000 -2.7%
12.27
US$1,227,000 		100,000 -2.7% 12.27 US$1,227,000
2017-12-07 2017-12-07 PlS Planned sale
3.8
Thorp Clay
Large shareholder
5,000 -0.1%
6.13
US$30,650 		5,000 -0.1% 6.13 US$30,650
2017-12-07 2017-12-06 PlS Planned sale
3.8
Thorp Clay
Large shareholder
15,000 -0.4%
6.09
US$91,350 		15,000 -0.4% 6.09 US$91,350
2017-12-07 2017-12-05 PlS Planned sale
3.8
Thorp Clay
Large shareholder
15,000 -0.4%
6.37
US$95,550 		15,000 -0.4% 6.37 US$95,550
2017-11-16 2017-11-16 PlS Planned sale
3.8
Thorp Clay
Large shareholder
5,000 -0.1%
6.99
US$34,950 		5,000 -0.1% 6.99 US$34,950
2017-11-16 2017-11-15 PlS Planned sale
3.8
Thorp Clay
Large shareholder
15,000 -0.4%
6.99
US$104,850 		15,000 -0.4% 6.99 US$104,850
2017-11-16 2017-11-14 PlS Planned sale
3.8
Thorp Clay
Large shareholder
15,000 -0.4%
7.02
US$105,300 		15,000 -0.4% 7.02 US$105,300
2017-10-23 2017-10-19 PlS Planned sale
2.0
White Daniel H.

President and CEO

Executive Director
400 -1.1%
7.81
US$3,124 		400 -1.1% 7.81 US$3,124
2017-10-23 2017-10-19 PlS Planned sale
2.0
White Daniel H.

President and CEO

Executive Director
3,600 -0.8%
7.81
US$28,116 		3,600 -0.8% 7.81 US$28,116
2017-10-23 2017-10-18 PlS Planned sale
2.0
White Daniel H.

President and CEO

Executive Director
400 -1.1%
7.82
US$3,128 		400 -1.1% 7.82 US$3,128
2017-10-23 2017-10-18 PlS Planned sale
2.0
White Daniel H.

President and CEO

Executive Director
3,600 -0.7%
7.82
US$28,152 		3,600 -0.7% 7.82 US$28,152
2017-10-05 2017-10-05 PlS Planned sale
3.8
Thorp Clay
Non-Executive Director Large shareholder
6,000 -0.2%
8.34
US$50,040 		6,000 -0.2% 8.34 US$50,040
2017-10-05 2017-10-04 PlS Planned sale
3.8
Thorp Clay
Non-Executive Director Large shareholder
14,000 -0.4%
8.59
US$120,260 		14,000 -0.4% 8.59 US$120,260
2017-10-05 2017-10-03 PlS Planned sale
3.8
Thorp Clay
Non-Executive Director Large shareholder
15,000 -0.4%
8.64
US$129,600 		15,000 -0.4% 8.64 US$129,600
2017-09-15 2017-09-15 PlS Planned sale
3.8
Thorp Clay
Large shareholder
10,000 -0.3%
7.54
US$75,400 		10,000 -0.3% 7.54 US$75,400
2017-09-15 2017-09-14 PlS Planned sale
3.8
Thorp Clay
Large shareholder
6,000 -0.2%
7.52
US$45,120 		6,000 -0.2% 7.52 US$45,120
2017-09-15 2017-09-13 PlS Planned sale
3.8
Thorp Clay
Large shareholder
8,500 -0.2%
7.49
US$63,665 		8,500 -0.2% 7.49 US$63,665
Explore more

More insider trading research around Clearside Biomedical Inc

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America